These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2551145)

  • 1. Effects of canrenone on Na+,K+ ATPase activity, arterial pressure and plasma potassium concentration in uremic hemodialyzed patients.
    Quarello F; Boero R; Guarena C; Rosati C; Beltrame G; Colombo P; Berto IM; Aimino M; Formica M; Piccoli G
    Adv Exp Med Biol; 1989; 252():371-6. PubMed ID: 2551145
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of saline infusion and canrenone on erythrocyte Na+,K+ pump activity.
    Boero R; Guarena C; Deabate MC; Rosati C; Forneris G; Quarello F; Piccoli G
    Kidney Int Suppl; 1988 Sep; 25():S9-11. PubMed ID: 2846942
    [No Abstract]   [Full Text] [Related]  

  • 3. The interaction of canrenone with the Na+,K+ pump in human red blood cells.
    Garay RP; Diez J; Nazaret C; Dagher G; Abitbol JP
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):311-5. PubMed ID: 2991778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of canrenone on blood pressure in rats with reduced renal mass.
    Pamnani MB; Whitehorn WV; Clough DL; Haddy FJ
    Am J Hypertens; 1990 Mar; 3(3):188-95. PubMed ID: 2157466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocyte Na+, K+ pump inhibition after saline infusion in essentially hypertensive subjects: effects of canrenone administration.
    Boero R; Guarena C; Deabate MC; Rolando B; Rosati C; Quarello F; Piccoli G
    Int J Cardiol; 1989; 25 Suppl 1():S47-52. PubMed ID: 2620996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase.
    Finotti P; Palatini P
    J Pharmacol Exp Ther; 1981 Jun; 217(3):784-90. PubMed ID: 6262496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effect of canrenone in a model where endogenous ouabain-like factors are present.
    de Mendonça M; Grichois ML; Pernollet MG; Wauquier I; Trouillet-Thormann B; Meyer P; Devynck MA; Garay R
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):75-83. PubMed ID: 2450260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do canrenone and 6,7-dihydroxylated derivatives compete with ouabain at the same site on Na,K-ATPase?
    Tal DM; Karlish SJ
    Mol Pharmacol; 1988 Sep; 34(3):245-9. PubMed ID: 2843743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrocyte Na,K pump in uremia. Acute correction of a transport defect by hemodialysis.
    Izumo H; Izumo S; DeLuise M; Flier JS
    J Clin Invest; 1984 Aug; 74(2):581-8. PubMed ID: 6086716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Membrane activity of canrenone in the normotensive subject: evaluation and significance].
    Ollivier JP; Delamourd L; Leglise D
    Sem Hop; 1981 Mar 8-15; 57(9-10):495-8. PubMed ID: 6261395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium pump and Na+/H+ activities in uremic erythrocytes. A microcalorimetric and pH-metric study.
    Kovacic H; Gallice P; Brunet P; Berland Y; Crevat A
    Clin Chim Acta; 1997 Mar; 259(1-2):31-40. PubMed ID: 9086292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of natriuretic hormones and Na+ transport in the antihypertensive action of canrenone.
    Hannaert P; de Mendonca M; Grichois ML; Nazaret C; Abitbol JP; Garay R
    Uremia Invest; 1985-1986; 9(2):195-201. PubMed ID: 2429426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone- and canrenone-induced changes in hepatic (Na+,K+)ATPase activity, surface membrane cholesterol and phospholipid, and fluorescence polarization in the rat.
    Miner PB; Sneller M; Crawford SS
    Hepatology; 1983; 3(4):481-8. PubMed ID: 6305816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of alteration of sodium potassium pump of erythrocytes from patients with chronic renal failure.
    Cheng JT; Kahn T; Kaji DM
    J Clin Invest; 1984 Nov; 74(5):1811-20. PubMed ID: 6094614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dialysis on circulating Na,K ATPase inhibitor in uremic patients.
    Stokes GS; Norris LA; Marwood JF; Johnston H; Caterson RJ
    Nephron; 1990; 54(2):127-33. PubMed ID: 2156180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of active sodium and potassium transport in erythrocytes in children with different stages of symptomatic uremia.
    Sigström L
    Acta Paediatr Scand; 1981; 70(3):361-8. PubMed ID: 6454327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of dialysis on Na+/K+-ATP-ase activity in uremic children].
    Vásárhelyi B; Reusz G; Sallay P; Tulassay T
    Orv Hetil; 1996 Oct; 137(40):2193-6. PubMed ID: 8927368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.
    Fedorova OV; Emelianov IV; Bagrov KA; Grigorova YN; Wei W; Juhasz O; Frolova EV; Marshall CA; Lakatta EG; Konradi AO; Bagrov AY
    J Hypertens; 2015 Aug; 33(8):1602-10. PubMed ID: 26136067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aldosterone antagonist canrenone on plasma aldosterone concentration and plasma renin activity, and on the excretion of aldosterone and electrolytes by man.
    Erbler HC; Wernze H; Hilfenhaus M
    Eur J Clin Pharmacol; 1976 Feb; 9(4):253-7. PubMed ID: 971711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Na-K ATPase inhibitor activity and intracellular ions during hemodialysis.
    Krzesinski JM; Du F; Pequeux ML; Rorive GL
    Int J Artif Organs; 1993 Jan; 16(1):23-30. PubMed ID: 8384605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.